Latrunculin A - CAS:76343-93-6

您当前的位置：

Latrunculin A (Synonyms:LAT-A)

目录号 : KM16530 CAS No. : 76343-93-6 纯度 : ≥97%

Data Sheet SDS 产品使用指南

Latrunculin A (LAT-A) 是从红海海绵 Latrunculia magnifica 中得到的一种毒素，能够与肌动蛋白 (actin) 单体结合，抑制肌动蛋白聚集，对 ATP-actin，ADP-Pi-actin，ADP-actin 和 G-actin 的 K_d 值分别为 0.1，0.4，4.7 μM 和 0.19 μM。

规格	价格	是否有货	数量
100µg		In-stock
1mg		In-stock

加入购物车大包装询价

Other Forms of Rapamycin:

Cytochalasin D In-stock
Latrunculin A In-stock
Cytochalasin B In-stock

KKL Med 的所有产品和服务仅用于科学研究，不能被用于人体，兽医，我们也不向个人提供产品和服务。

生物活性

Latrunculin A (LAT-A) is a toxin isolated from the red sea sponge Latrunculia magnifica, binds to actin monomers, inhibits polymerization of actin, with K_ds of 0.1, 0.4, 4.7 μM and 0.19 μM for ATP-actin, ADP-Pi-actin, ADP-actin and G-actin, respectively.

IC₅₀&Target

Kd: 0.1 μM (ATP-actin), 0.4 μM (ADP-Pi-actin), 4.7 μM (ADP-actin), 0.19 μM (G-actin)

体外研究

LatruncuLin A (50-1000 nM) exhibits potent anti invasive activity against human prostate cancer PC-3M cells, inhibiting PC-3M-CT+sphere depolymerization and cell migration.

LauncuLin A (3-30 μM) inhibited hypoxia induced HIF-1 activation, and the IC₅₀ value in human breast cancer T47D cells was 6.7 μM [1].

LatruncuLin A (0-0.2 μM, 4 hours) has a significant inhibitory effect on HuR levels in human liver cancer HepG2 cells at high concentrations (e.g. 0.2 μM), while only inhibiting HuR at 0.02 μM, but has no inhibitory effect on human liver cancer Huh7 cells at high concentrations [2].

LatruncuLin A (0.1 μM, 24 hours) can significantly reduce cell migration and inhibit cell proliferation in the human liver cancer cell line HepG2 [2].

体内研究

LatruncuLin A (intraperitoneal injection, 0.05 mg/kg, administered three times in the first 20 days, 120 days) has strong anti-tumor effects on male BALB/c nude mouse models infected with adenocarcinoma (MKN45) or cancer (NugC-4).

Animal Model:	Male BALB/c nude mice models infected with adenocarcinoma (MKN45) or carcinoma (NUGC-4)
Dosage:	0.05 mg/kg
Administration:	Intraperitoneal injection; three doses in the first 20 days; 120 days
Result:	Extended the mean life expectancy to 23.5 days comparing to control of 16 days in adenocarcinoma (MKN45) mice and the mean survival time was 42 days comparing to untreated of 31 days in carcinoma (NUGC-4) mice.

分子式

C₂₂H₃₁NO₅S

分子量

421.55

CAS号

76343-93-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, 2 years

临床试验

纯度： ≥97%

Data Sheet

SDS

产品使用指南

[1]. Khalid A El Sayed, et al. Latrunculin A and its C-17-O-carbamates inhibit prostate tumor cell invasion and HIF-1 activation in breast tumor cells. J Nat Prod. 2008 Mar;71(3):396-402.

[2]. Anke Doller, et al. The cytoskeletal inhibitors latrunculin A and blebbistatin exert antitumorigenic properties in human hepatocellular carcinoma cells by interfering with intracellular HuR trafficking. Exp Cell Res. 2015 Jan 1;330(1):66-80.

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量

浓度

体积

分子量*

重置计算

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2

浓度

体积

浓度

体积

重置计算

动物实验计算换算器

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系客服为您提供正确的澄清溶液配方）

% DMSO

% Tween 80

% ddH₂O

% DMSO

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系客服）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

配置后的溶液总体积：

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

Other Forms of Rapamycin:

KKL 顾客使用本产品发表的 0 篇科研文献

The molarity calculator equation

The dilution calculator equation

动物实验计算换算器